|
|
|
市場調查報告書
品牌及策略：多發性硬化症
Brands & Strategies: Multiple Sclerosis
|
本報告已在2011年12月21日停止出版。
本報告書內容包括：多發性硬化症治療藥相關企業分析、市場預測等。內容綱要摘記如下：
實施概要
第1章 多發性硬化症的患者人數
第2章 多發性硬化症的治療概要
- 主要競爭
- 目前的治療方法
- 基因重組β干擾素
- 變換縮氨酸配體
- 化學療法
- 單株抗體
- 副腎皮質荷爾蒙
- 免疫抑制劑
第3章 多發性硬化症治療的主要市場
第4章 競爭分析
- 概要
- 競爭情勢
- Biogen Idec
- Teva Pharmaceuticals
- Serono SA
- Schering AG
第5章 補充資料
圖表
Abstract
In This Issue...
The market for multiple sclerosis (MS) therapies is dominated by a handful of
key players-Biogen Idec, Serono, Schering AG, and Teva-who produce premium
priced therapies including interferon-beta (Biogen Idec' s Avonex, Serono' s
Rebif, and Schering AG' s Betaseron) and Teva' s Copaxone. Despite the
commercial success of existing drugs, a high level of unmet clinical need
exists, providing ample market opportunity for new treatments that demonstrate
improved efficacy, tolerability, and convenience in comparison to currently
available treatments.
Questions Answered in This Report
- Competitive dynamics: Market-leading recombinant interferon-beta
therapies, such as Biogen Idec' s Avonex, Serono' s Rebif, and Schering AG' s
Betaseron, are involved in an intensely competitive arena-from both a
within-class perspective and from the other leading MS agent, Teva' s altered
peptide ligand, Copaxone. How have the leading competitors positioned
their brands for success? Which interferon-beta drugs will continue to
succeed in the market?
- Market dynamics: The introduction of guidelines for the approval of
biosimilar medicinal products in Europe will dramatically affect the market
for recombinant interferon-beta. When will biosimilar interferon-beta
launch in the major markets? What level of uptake will biosimilars experience
and which branded drugs will be most affected?
- Brand dynamics: Following its withdrawal over safety concerns,
Biogen Idec' s Tysabri has relaunched following an in-depth review of the drug
by US and European regulators. How will Tysabri' s availability impact the
MS market? What effect will safety concerns have on Tysabri' s commercial
success?
- Key events: Few new drugs have been successfully developed for the
treatment of MS in recent years, leaving the market to established
competitors. What new drugs are forecast to enter the MS market between
2005 and 2010 and when will they launch? What products are being developed in
the major MS competitors' pipelines?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Market Analysis: Annualized 5-year sales forecasts presented by
region, drug class, molecule, and brand for 2005 to 2010, including a
breakdown of branded versus generic sales for each market and the impact of
key events during the forecast period. Annualized forecast of total prevalent
and diagnosed cases for each of the major markets from 2005 to 2010.
- Company Analysis: Detailed discussion of major competitors
including Biogen Idec, Teva Pharmaceuticals, Serono, and Schering AG.
Includes analysis of each company' s MS product portfolio, strategic
positioning, licensing strategy, post-marketing clinical trials, and
development pipeline.
- Brand Analysis: The report features an in-depth discussion of
leading brands in the MS market, including approval history, sales and market
position, SWOT analysis, annualized sales forecast, promotional efforts, and
on-going life cycle management initiatives.
Table of Contents
Table of Contents
Table of Exhibits
Executive Summary
Section 1: Multiple Sclerosis Patient Populations
- Background
- Multiple Sclerosis Prevalence and Diagnosis
- US
- Europe
- Japan
Section 2: Multiple Sclerosis Treatment Overview
- Major Competitors
- Exisiting Treatments
- Recombinant Interferon-β
- Altered Peptide Ligands
- Chemotherapeutics
- Monoclonal Antibodies
- Corticosteroids
- Immunosuppressants
Section 3: Major Markets for Multiple Sclerosis Treatment
- Market Overview
- MS Drug Sales by Region
- MS Drug Sales by Class
- Market Forecast
- Key Events
- Drug Pricing
- Formulary Placement
- Recombinant Interferon-β Market
- Altered Peptide Ligand Market
- Chemotherapeutic Market
- Monoclonal Antibody Market
- Corticosteroid Market
- Immunosuppressant Market
Section 4: Competitive Analysis
- Overview
- Competitive Landscape
- MS Market by Competitor
- Promotional Spending
Biogen Idec
- Product Portfolio
- Strategic Positioning
- Avonex
- Approval History
- Sales and Market Position
- Avonex Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Tysabri
- Approval History
- Sales and Market Position
- Tysabri Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Biogen Idec MS Pipeline
- Daclizumab
- Rituximab
- BG-12
- Pegylated Inferferon-β-1a
- LINGO-1 Inhibitor
Teva Pharmaceuticals
- Product Portfolio
- Strategic Positioning
- Copaxone
- Approval History
- Sales and Market Position
- Copaxone Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Teva Pharmaceuticals MS Pipeline
- Laquinimod
- TV-5010
- Oral Copaxone
Serono SA
- Product Portfolio
- Strategic Positioning
- Rebif
- Approval History
- Sales and Market Position
- Rebif Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Novantrone
- Approval History
- Sales and Market Position
- Novantrone Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Serono MS Product Pipeline
- Oral Cladribine
- MMP-12 Inhibitor
- JNK Inhibitor
- Interferon-β:Fc
- Osteopontin
Schering AG
- Product Portfolio
- Strategic Position
- Betaseron
- Approval History
- Sales and Market Position
- Betaseron Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Schering AG MS Pipeline
Section 5: Supplementary Market Analysis
Acronyms and Initialisms
Methodology
- Epidemiological Forecast Methodology
- Market Forecast Methodology
- Competitive Analysis Methodology
Table of Exhibits
Executive Summary
- Exhibit ES-1: MS Market Value, Major Markets, 2005-2010
- Exhibit ES-2: MS Market by Competitor, 2005 and 2010
Section 1: Multiple Sclerosis Patient Populations
- Prevalent and Diagnosed MS Cases (Thousands), Major Markets, 2005-2010
- Prevalent and Diagnosed MS Cases (Thousands), US, 2005-2010
- Total Prevalent Cases of MS (Thousands), by Country, Europe, 2005-2010
- Prevalent and Diagnosed MS Cases, Japan, 2005-2010
Section 2: Multiple Sclerosis Treatment Overview
- Exhibit 2-1: MS Drugs, by Major Competitor
- Exhibit 2-2: MS Drugs, by Drug Class
Section 3: Major Markets for Multiple Sclerosis Treatment
- Exhibit 3-1: MS Market ($US), Major Markets, 2005-2010 (Graphical Format)
- Exhibit 3-2: MS Market ($US), Major Markets, 2005-2010 (Tabular Format)
- Exhibit 3-3: MS Market ($US), by Country, 2005-2010
- Exhibit 3-4: MS Market, by Country as a % of Total, 2005 and 2010
- Exhibit 3-5: MS Market ($US), by Drug Class, 2005-2010
- Exhibit 3-6: Key Events , MS Market, 2005-2010
- Exhibit 3-7: Price to Treat per Day ($US), Recombinant Interferon-β,
2005-2010
- Exhibit 3-8: Recombinant Interferon-β Pricing ($US), Brand vs.
Generic Price, 2005
- Exhibit 3-9: Price to Treat per Day ($US), Altered Peptide Ligands,
2005-2010
- Exhibit 3-10: Price to Treat per Day ($US), Chemotherapeutics, 2005-2010
- Exhibit 3-11: Chemotherapeutic Pricing ($US), Brand vs. Generic Price, 2005
- Exhibit 3-12: Price to Treat per Day ($US), Monoclonal Antibodies,
2005-2010
- Exhibit 3-13: Price to Treat per Day ($US), Corticosteroids, 2005-2010
- Exhibit 3-14: Corticosteroid Pricing ($US), Brand vs. Generic Price, 2005
- Exhibit 3-15: Price to Treat per Day ($US), Immunosuppressants, 2005-2010
- Exhibit 3-16: Immunosuppressant Pricing ($US), Brand vs. Generic Price,
2005
- Exhibit 3-17: US Formulary Placement of MS-Indicated Therapies
- Exhibit 3-18: Recombinant Interferon-β Market ($US), 2005-2010
- Exhibit 3-19: Recombinant Interferon-β Market ($US), by Country,
2005-2010
- Exhibit 3-20: Recombinant Interferon-β Market ($US), by Drug,
2005-2010
- Exhibit 3-21: Recombinant Interferon-β Branded Market Share, by Brand
and Country, 2005 and 2010
- Exhibit 3-22: Altered Peptide Ligand Market ($US), 2005-2010
- Exhibit 3-23: Altered Peptide Ligand Market ($US), by Country, 2005-2010
- Exhibit 3-24: Chemotherapeutics Market ($US), 2005-2010
- Exhibit 3-25: Chemotherapeutics Market ($US), by Country, 2005-2010
- Exhibit 3-26: Chemotherapeutics Market ($US), by Drug, 2005-2010
- Exhibit 3-27: Monoclonal Antibody Market ($US), 2005-2010
- Exhibit 3-28: Monoclonal Antibody Market ($US), by Country, 2005-2010
- Exhibit 3-29: Monoclonal Antibody Market ($US), by Drug, 2005-2010
- Exhibit 3-30: Corticosteroid Market ($US), 2005-2010
- Exhibit 3-31: Corticosteroid Market ($US), by Country, 2005-2010
- Exhibit 3-32: Corticosteroid Market ($US), by Drug, 2005-2010
- Exhibit 3-33: Immunosuppressant Market ($US), 2005-2010
- Exhibit 3-34: Immunosuppressant Market ($US), by Country, 2005-2010
- Exhibit 3-35: Imuran Market ($US) by Drug, 2005-2010
Section 4: Competitive Analysis
- Exhibit 4-1: MS Market Competitive Position, 2005 and 2010
- Exhibit 4-2: MS Market ($US), by Company, 2005-2010
- Exhibit 4-3: Promotional Spend for MS Therapies, by Company, 2005
- Exhibit 4-4: Promotional Spending Among First-Line MS Therapies, 2005
- Exhibit 4-5: Summary of Biogen Idec' s MS Product Portfolio
- Exhibit 4-6: Biogen Idec MS Revenues ($US), by Brand, 2005-2010
- Exhibit 4-7: Timeline of Avonex Regulatory Approvals in the Seven Major
Pharmaceutical Markets
- Exhibit 4-8: Key Clinical Trials Supporting Avonex' Regulatory Approvals
- Exhibit 4-9: Timeline of Tysabri Regulatory Approvals in the Seven Major
Pharmaceutical Markets
- Exhibit 4-10: Key Clinical Trials Supporting Tysabri' s Regulatory Approvals
- Exhibit 4-11: Summary of Teva Pharmaceuticals MS Product Portfolio
- Exhibit 4-12: Timeline of Copaxone Regulatory Approvals in the Seven Major
Pharmaceutical Markets
- Exhibit 4-13: Key Clinical Trials Supporting Copaxone' s Regulatory
Approvals
- Exhibit 4-14: Summary of Serono SA' s MS Product Portfolio
- Exhibit 4-15: Timeline of Rebif Regulatory Approvals in the Seven Major
Pharmaceutical Markets
- Exhibit 4-16: Key Clinical Trials Supporting Rebif' s Regulatory Approvals
- Exhibit 4-17: Key Clinical Trials Supporting Novantrone' s Regulatory
Approvals
- Exhibit 4-18: Summary of Schering AG' s MS Product Portfolio
- Exhibit 4-19: Timeline of Betaseron Regulatory Approvals in the Seven
Major Pharmaceutical Markets
- Exhibit 4-20: Key Clinical Trials Supporting Betaseron' s Regulatory
Approvals
- Exhibit 4-21: Key Clinical Trials Supporting Betaseron' s Regulatory
Approvals, Continued
Section 5: Supplementary Market Analysis
- Exhibit 5-1: Total Interferon-β-1a (IM) Market ($US), by Country,
2005-2010
- Exhibit 5-2: Avonex Market ($US), by Country, 2005-2010
- Exhibit 5-3: Total Interferon-β-1a (SC) Market ($US), by Country,
2005-2010
- Exhibit 5-4: Rebif Market ($US), by Country, 2005-2010
- Exhibit 5-5: Total Interferon-β-1b Market ($US), by Country, 2005-2010
- Exhibit 5-6: Betaseron Market ($US), by Country, 2005-2010
- Exhibit 5-7: Total Mitoxantrone Market ($US), by Country, 2005-2010
- Exhibit 5-8: Novantrone Market ($US), by Country, 2005-2010
- Exhibit 5-9: Total Cyclophosphamide Market ($US), by Country, 2005-2010
- Exhibit 5-10: Cytoxan Market ($US), by Country, 2005-2010
- Exhibit 5-11: Total Methotrexate Market ($US), by Country, 2005-2010
- Exhibit 5-12: Rheumatrex Market ($US), by Country, 2005-2010
- Exhibit 5-13: Methylprednisolone Market ($US), by Drug, 2005-2010
- Exhibit 5-14: Solu-Medrol Market ($US), by Country, 2005-2010
- Exhibit 5-15: Total Prednisone Market ($US), by Country, 2005-2010
- Exhibit 5-16: Deltasone Market ($US), by Country, 2005-2010
- Exhibit 5-17: Total Azathioprine Market ($US), by Country, 2005-2010
- Exhibit 5-18: Imuran Market ($US), by Country, 2005-2010
|
 |
